“Complete Response” Letters
This article was originally published in Pharmaceutical Approvals Monthly
FDA stopped issuing “approvable” and “not approvable” letters in favor of “complete response” letters on Aug. 11, 2008. The following chart lists “complete response” actions recently announced, as well as still-pending “approvable” and “not approvable” actions.
You may also be interested in...
Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.
House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.
The new Eudamed database may be delayed for two years, but the European Commission wants to allow early access to Single Registration Numbers before Eudamed goes live in 2022 to aid voluntary registration in the interim.